Other measures are needed to assess patients’ cardiovascular risks
- Among patients with chronic kidney disease, those with very low kidney function had a higher risk of having a heart attack than those with higher kidney function over a four-year period.
- The link between higher LDL cholesterol and heart attack risk was weaker for patients with very low kidney function than for patients with higher kidney function.
- 60 million people globally have chronic kidney disease.
LDL cholesterol is not a useful marker of heart disease risk in patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The finding suggests that other measurements should be used to assess kidney disease patients’ cardiovascular health.
High LDL cholesterol is a strong marker of heart disease risk in the general population, but its use in people with chronic kidney disease (CKD) is unclear. To investigate, Marcello Tonelli, MD, FRCPC (University of Alberta, in Edmonton, Canada) and his colleagues studied 836,060 adults with CKD from the Alberta Kidney Disease Network between 2002 and 2009.
During an average follow-up of four years, 7762 patients were hospitalized for heart attacks, most of whom had the lowest levels of kidney function at the start of the study. Despite their higher overall risk of having a heart attack, the link between higher LDL cholesterol and heart attack risk was weaker for these patients than for patients with higher kidney function.
“This indicates that, although people with impaired kidney function are at high risk of cardiovascular events, LDL cholesterol is less useful as a marker of risk in this population,” said Dr. Tonelli. “This in turn suggests that, unlike in the general population, criteria for cardioprotective treatments such as statins should not be based on LDL cholesterol levels in people with chronic kidney disease, and it argues instead for an approach that is based on absolute cardiovascular risk.”
In an accompanying editorial, Julie Lin, MD (Genzyme Corporation and Brigham and Women’s Hospital) noted that further study of kidney dysfunction and cardiovascular risk represents an important area of healthcare research. “The very large total at-risk population of CKD and end stage renal disease patients who will experience morbidity and mortality from cardiovascular disease is calling out for more research to lead directly to improved management and outcomes as soon as possible.”
Study co-authors include Paul Muntner, PhD, Anita Lloyd, Braden Manns, MD, Scott Klarenbach, MD, Neesh Pannu, MD, Matthew James, MD, PhD, and Brenda Hemmelgarn MD, PhD.
Disclosures: This work was supported by an interdisciplinary team grant from the Alberta Heritage Foundation for Medical Research (AHFMR). Drs. Hemmelgarn, Tonelli, Klarenbach and Manns were supported by career salary awards from AHFMR. Dr. Tonelli was also supported by a Government of Canada Research Chair in the optimal care of people with chronic kidney disease, and Dr. Hemmelgarn by the Roy and Vi Baay Chair in Kidney Research. Drs. Hemmelgarn, Klarenbach, Manns, and Tonelli were all supported by a joint initiative between Alberta Health and Wellness and the Universities of Alberta and Calgary. Dr. Muntner receives research funding from Amgen Inc. Dr. Tonelli has served on advisory boards for Merck; honoraria were donated to charity.
The article, entitled “Association between LDL-C and Risk of Myocardial Infarction in CKD,” appeared online at http://jasn.asnjournals.org/ on May 16, 2013, doi: 10.1681/ASN.2012080870.
The editorial, entitled “A Piece of the Puzzle in the Cardiorenal Conundrum,” appeared online at http://jasn.asnjournals.org/ on May 16, 2013, doi: 10.1681/ASN.2013040420.